Pfizer stock ticks higher on new FDA approval for prostate cancer drug

Pfizer Inc. PFE, -0.68% shares ticked higher in the extended session Monday after the drug maker said the Food and Drug Administration approved a new indication for a cancer drug it makes with Astellas Pharma Inc. 4503, -1.25%. Pfizer shares rose 1.2% after hours, following a 2.1% advance to close the regular session at $39.14. Pfizer said the FDA approved Xtandi to treat patients with metastatic castration-sensitive prostate cancer, or prostate cancer that spreads to other parts of the body and is responsive to treatments that lower testosterone. Xtandi is already approved to treat non-metastatic and metastatic castration-resistant prostate cancer.